https://cea.digitellinc.com/p/cf/inaugural-psychiatry-summit-2022-6
https://cea.digitellinc.com/p/cf/ips-posters-2022-12
https://cea.digitellinc.com/p/s/adjunctive-lumateperone-iti-007-in-the-treatment-of-bipolar-depression-results-from-a-randomized-clinical-trial-17
https://cea.digitellinc.com/p/s/attitudes-and-beliefs-about-prenatal-cannabis-use-among-postpartum-women-with-and-without-a-personal-history-of-cannabis-use-22
https://cea.digitellinc.com/p/s/decreasing-psych-polypharmacy-in-correctional-population-strategies-for-pharmacist-led-interventions-27
https://cea.digitellinc.com/p/s/development-of-the-mind-td-questionnaire-as-a-screening-tool-for-tardive-dyskinesia-32
https://cea.digitellinc.com/p/s/differential-access-to-child-psychiatry-37
https://cea.digitellinc.com/p/s/direct-and-indirect-costs-associated-with-major-depressive-disorder-42
https://cea.digitellinc.com/p/s/dispensing-practices-for-psychotropic-medications-amongst-pharmacists-in-karachi-pakistan-47
https://cea.digitellinc.com/p/s/effectiveness-of-buspirone-compared-to-benzodiazepine-in-the-treatment-of-posttraumatic-stress-disorder-ptsd-symptoms-52
https://cea.digitellinc.com/p/s/effects-of-cariprazine-on-cognition-in-patients-with-bipolar-mania-or-mixed-states-pooled-analysis-from-3-randomized-controlled-studies-57
https://cea.digitellinc.com/p/s/efficacy-of-cariprazine-in-patients-with-bipolar-depression-and-baseline-anxiety-a-pooled-post-hoc-analysis-62
https://cea.digitellinc.com/p/s/gender-differences-in-nonmedical-use-of-prescription-medications-in-primary-care-67
https://cea.digitellinc.com/p/s/lumateperone-iti-007-in-the-treatment-of-bipolar-depression-efficacy-across-symptoms-72
https://cea.digitellinc.com/p/s/measurement-based-care-in-psychiatry-the-benefits-and-barriers-77
https://cea.digitellinc.com/p/s/mobile-based-contingency-management-to-promote-adherence-to-daily-self-monitoring-of-chronic-pain-related-variables-implications-for-mental-health-practitioners-82
https://cea.digitellinc.com/p/s/once-daily-valbenazine-is-effective-for-tardive-dyskinesia-in-elderly-patients-65-years-87
https://cea.digitellinc.com/p/s/post-traumatic-stress-after-birth-in-a-population-of-women-with-opioid-use-disorder-92
https://cea.digitellinc.com/p/s/prevalence-and-risk-factors-of-frequent-mental-distress-in-the-us-population-during-the-covid-19-pandemic-97
https://cea.digitellinc.com/p/s/quality-improvement-project-using-music-therapy-to-decrease-the-incidence-of-aggression-for-adult-patients-diagnosed-with-mental-disorder-in-inpatient-psychiatric-units-102
https://cea.digitellinc.com/p/s/real-world-long-term-outcomes-with-valbenazine-in-adults-with-tardive-dyskinesia-107
https://cea.digitellinc.com/p/s/evidence-based-case-report-relationship-between-mind-mediterranean-dash-diet-intervention-for-neurodegenerative-delay-and-cognitive-function-in-elderly-112
https://cea.digitellinc.com/p/s/the-impact-of-covid-19-on-individuals-with-asd-in-the-us-parent-perspectives-on-social-and-support-concerns-117
https://cea.digitellinc.com/p/s/the-real-world-health-resource-use-and-costs-of-misdiagnosing-bipolar-i-disorder-a-retrospective-database-analysis-122
https://cea.digitellinc.com/p/s/the-use-of-ketamine-for-the-treatment-of-ptsd-a-review-of-the-literature-127
https://cea.digitellinc.com/p/s/utilization-of-low-dose-depakote-for-the-treatment-of-delirium-in-hospitalized-adults-a-retrospective-analysis-of-depakote-treatment-protocol-132
https://cea.digitellinc.com/p/s/opening-remarks-and-keynote-address-the-pursuit-of-mental-health-equity-137
https://cea.digitellinc.com/p/s/break-142
https://cea.digitellinc.com/p/s/translating-novel-mdd-treatment-principles-into-practice-147
https://cea.digitellinc.com/p/s/wellness-break-flowing-tadasana-yoga-152
https://cea.digitellinc.com/p/s/coordination-of-care-between-referring-psychiatrist-and-treatment-center-provider-157
https://cea.digitellinc.com/p/s/break-162
https://cea.digitellinc.com/p/s/advancing-patient-care-in-bipolar-depression-167
https://cea.digitellinc.com/p/s/poster-hall-172
https://cea.digitellinc.com/p/s/break-177
https://cea.digitellinc.com/p/s/why-do-schizophrenia-patients-relapse-and-what-should-we-do-182
https://cea.digitellinc.com/p/s/wellness-break-hips-and-shoulders-yoga-187
https://cea.digitellinc.com/p/s/new-mechanisms-new-medications-for-schizophrenia-and-closing-remarks-192
https://cea.digitellinc.com/p/s/opening-remarks-and-pharmacological-strategies-for-treatment-resistant-depression-197
https://cea.digitellinc.com/p/s/break-202
https://cea.digitellinc.com/p/s/targeting-anxiety-symptoms-in-mood-disorder-patients-207
https://cea.digitellinc.com/p/s/wellness-break-hands-neck-and-wrists-yoga-212
https://cea.digitellinc.com/p/s/myth-busting-in-psychopharmacology-217
https://cea.digitellinc.com/p/s/break-222
https://cea.digitellinc.com/p/s/potential-drugs-of-abuse-as-antidepressants-227
https://cea.digitellinc.com/p/s/poster-hall-232
https://cea.digitellinc.com/p/s/break-237
https://cea.digitellinc.com/p/s/treatment-of-bipolar-unipolar-as-a-spectrum-disorder-242
https://cea.digitellinc.com/p/s/wellness-break-hips-and-low-back-yoga-247
https://cea.digitellinc.com/p/s/a-bold-panoramic-grasp-of-tardive-dyskinesia-and-closing-remarks-252
https://cea.digitellinc.com/p/s/opening-remarks-and-fireside-chat-mood-disorders-in-special-populations-257
https://cea.digitellinc.com/p/s/break-262
https://cea.digitellinc.com/p/s/managing-schizophrenia-patients-with-cardiometabolic-risk-and-comorbidities-267
https://cea.digitellinc.com/p/s/wellness-break-shoulders-and-side-seams-yoga-272
https://cea.digitellinc.com/p/s/digital-transformation-in-mental-health-277
https://cea.digitellinc.com/p/s/break-282
https://cea.digitellinc.com/p/s/treatment-resistant-bipolar-disorders-287
https://cea.digitellinc.com/p/s/poster-hall-292
https://cea.digitellinc.com/p/s/wellness-break-three-part-breath-meditation-297
https://cea.digitellinc.com/p/s/targeting-attentional-complaints-across-dsm-5-categories-a-transdiagnostic-approach-and-closing-remarks-302
https://cea.digitellinc.com/p/s/welcome-portrait-337
https://cea.digitellinc.com/p/s/welcome-sponsors-341
https://cea.digitellinc.com/p/s/agenda-2sec-342
https://cea.digitellinc.com/p/cf/2nd-annual-movement-disorders-summit-344
https://cea.digitellinc.com/p/s/opening-remarks-and-targeting-cgrp-for-the-treatment-of-migraine-345
https://cea.digitellinc.com/p/s/break-346
https://cea.digitellinc.com/p/s/session-choice-page-347
https://cea.digitellinc.com/p/s/non-accredited-product-theater-on-tbd-348
https://cea.digitellinc.com/p/s/management-of-neuropsychiatric-features-in-alzheimers-disease-dementia-349
https://cea.digitellinc.com/p/s/a-changing-treatment-paradigm-of-myasthenia-gravis-a-focus-on-novel-targeted-treatments-350
https://cea.digitellinc.com/p/s/planning-ahead-development-of-a-seizure-action-plan-with-rescue-medications-351
https://cea.digitellinc.com/p/s/diagnosis-and-management-of-parkinsons-disease-dementia-and-closing-remarks-352
https://cea.digitellinc.com/p/s/opening-remarks-and-distinguishing-tardive-dyskinesia-from-other-drug-induced-movement-disorders-353
https://cea.digitellinc.com/p/s/managing-advanced-parkinsons-disease-adjunctive-therapies-354
https://cea.digitellinc.com/p/s/hyperkinetic-movement-disorders-importance-of-differential-diagnosis-when-symptoms-overlap-355
https://cea.digitellinc.com/p/s/beyond-pharmacotherapy-advancements-in-surgical-therapies-for-parkinsons-disease-356
https://cea.digitellinc.com/p/s/updates-in-diagnosis-and-treatment-of-essential-tremor-and-closing-remarks-357
https://cea.digitellinc.com/p/s/break-359
https://cea.digitellinc.com/p/s/break-360
https://cea.digitellinc.com/p/s/break-361
https://cea.digitellinc.com/p/s/break-362
https://cea.digitellinc.com/p/s/break-363
https://cea.digitellinc.com/p/s/break-364
https://cea.digitellinc.com/p/s/break-365
https://cea.digitellinc.com/p/s/break-366
https://cea.digitellinc.com/p/cf/jan-2023-critical-care-congress-367
https://cea.digitellinc.com/p/s/habpvabp-strategies-for-early-effective-therapy-in-critically-ill-patients-369
https://cea.digitellinc.com/p/cf/cea-proce-370
https://cea.digitellinc.com/p/s/delivering-patient-centered-equitable-care-in-anemia-of-ckd-expert-insights-on-translating-progress-to-practice-to-minimize-burden-of-disease-and-healthcare-disparities-371
https://cea.digitellinc.com/p/s/examining-advances-in-ovarian-cancer-and-strategies-to-promote-optimal-and-equitable-care-372
https://cea.digitellinc.com/p/s/management-of-eosinophilic-esophagitis-opportunities-for-pharmacists-to-increase-awareness-and-optimize-care-373
https://cea.digitellinc.com/p/cf/cea-2nd-annual-psychiatry-summit-378
https://cea.digitellinc.com/p/cf/cea-2nd-annual-psychiatry-summit-poster-hall-381
https://cea.digitellinc.com/p/s/opening-remarks-and-fireside-chat-on-reimagining-mental-health-383
https://cea.digitellinc.com/p/s/give-it-a-shot-evidence-for-early-use-of-lai-antipsychotics-384
https://cea.digitellinc.com/p/s/embracing-technology-in-mental-health-practice-385
https://cea.digitellinc.com/p/s/selection-page-386
https://cea.digitellinc.com/p/s/the-efficacy-and-safety-profile-of-an-adjunctive-therapy-for-adult-patients-with-major-depressive-disorder-mdd-387
https://cea.digitellinc.com/p/s/identifying-and-managing-substance-use-disorders-388
https://cea.digitellinc.com/p/s/augmenting-pharmacotherapies-in-mdd-and-closing-remarks-389
https://cea.digitellinc.com/p/s/opening-remarks-and-aiming-to-optimize-tardive-dyskinesia-care-390
https://cea.digitellinc.com/p/s/postpartum-depression-advances-in-diagnosis-and-management-391
https://cea.digitellinc.com/p/s/optimizing-diagnosis-and-treatment-choice-in-bipolar-disorder-392
https://cea.digitellinc.com/p/s/selection-page-393
https://cea.digitellinc.com/p/s/moving-forward-an-informed-approach-to-the-diagnosis-and-treatment-of-tardive-dyskinesia-394
https://cea.digitellinc.com/p/s/strategies-for-identifying-and-managing-generalized-anxiety-disorder-395
https://cea.digitellinc.com/p/s/addressing-challenges-in-mental-health-treatment-for-children-and-adolescents-396
https://cea.digitellinc.com/p/s/opening-and-you-snooze-you-lose-strategies-for-early-diagnosis-and-treatment-of-narcolepsy-397
https://cea.digitellinc.com/p/s/paying-attention-to-treatment-related-adverse-events-in-adhd-398
https://cea.digitellinc.com/p/s/modulators-of-glutamate-and-gaba-for-mdd-399
https://cea.digitellinc.com/p/s/incorporating-novel-treatment-options-into-schizophrenia-management-400
https://cea.digitellinc.com/p/s/managing-the-manifestations-of-trauma-and-closing-remarks-401
https://cea.digitellinc.com/p/s/lumateperone-for-treatment-of-bipolar-i-or-ii-depression-evaluation-of-extrapyramidal-and-motor-symptoms-in-late-phase-clinical-trials-404
https://cea.digitellinc.com/p/s/attention-deficit-disorder-a-path-to-diagnosis-405
https://cea.digitellinc.com/p/s/wernicke-korsakoff-syndrome-despite-prevention-and-treatment-407
https://cea.digitellinc.com/p/s/efficacy-of-adjunctive-cariprazine-on-anxiety-symptoms-in-patients-with-major-depressive-disorder-and-baseline-anxiety-post-hoc-408
https://cea.digitellinc.com/p/s/efficacy-of-lumateperone-in-pooled-short-term-late-phase-clinical-trials-for-treatment-of-major-depressive-episodes-associated-with-bipolar-ii-disorder-409
https://cea.digitellinc.com/p/s/increased-number-of-lymphocytes-during-a-psychotic-episode-a-retrospective-longitudinal-observational-cohort-study-411
https://cea.digitellinc.com/p/s/rare-earth-elements-impregnation-as-potential-biomarker-of-idiopathic-environmental-intolerance-attributed-to-electromagnetic-fields-414
https://cea.digitellinc.com/p/s/from-suicidal-ideation-to-suicide-attempt-precipitating-factors-415
https://cea.digitellinc.com/p/s/efficacy-of-cariprazine-as-adjunctive-treatment-of-major-depressive-disorder-in-patients-with-anxiety-at-baseline-a-post-hoc-analysis-416
https://cea.digitellinc.com/p/s/full-spectrum-efficacy-of-cariprazine-on-manic-and-depressive-poles-of-bipolar-i-disorder-in-patients-experiencing-manic-or-depressive-episodes-417
https://cea.digitellinc.com/p/s/economic-outcomes-with-adjunctive-cariprazine-and-other-atypical-antipsychotics-in-patients-with-major-depressive-disorder-418
https://cea.digitellinc.com/p/s/body-image-disorder-among-patients-with-rectal-cancer-419
https://cea.digitellinc.com/p/s/relationship-and-sexual-satisfaction-before-and-after-rectal-cancer-treatment-420
https://cea.digitellinc.com/p/s/oncologists-experience-in-delivering-bad-news-a-cross-sectional-study-in-tunisia-424
https://cea.digitellinc.com/p/s/advancing-suicide-prevention-best-practices-in-non-psychiatric-hospital-units-through-advanced-practice-nursing-425
https://cea.digitellinc.com/p/s/olfactory-hallucinations-as-a-component-of-kandinsky-clerambault-syndrome-426
https://cea.digitellinc.com/p/s/transient-delusional-parasitosis-427
https://cea.digitellinc.com/p/s/possession-trance-disorder-with-spirit-specific-movements-428
https://cea.digitellinc.com/p/s/older-and-elderly-patients-with-tardive-dyskinesia-exhibit-substantial-improvements-and-maintenance-of-psychiatric-stability-during-long-term-valbenazine-treatment-429
https://cea.digitellinc.com/p/s/crushing-valbenazine-capsule-contents-for-potential-addition-to-soft-foods-or-administration-via-g-tube-430
https://cea.digitellinc.com/p/s/healthcare-resource-utilization-with-adjunctive-cariprazine-and-other-atypical-antipsychotics-in-patients-with-major-depressive-disorder-431
https://cea.digitellinc.com/p/cf/best-of-asco-2023-432
https://cea.digitellinc.com/p/s/session-choice-page-login-433
https://cea.digitellinc.com/p/s/welcome-and-opening-remarks-plus-gynecologic-malignancies-434
https://cea.digitellinc.com/p/s/breast-cancer-435
https://cea.digitellinc.com/p/s/session-choice-page-436
https://cea.digitellinc.com/p/s/non-accredited-presentation-theater-real-world-case-discussion-intervene-with-jakafi-r-ruxolitinib-at-diagnosis-in-adults-with-intermediate-risk-or-high-risk-myleofibrosis-437
https://cea.digitellinc.com/p/s/hematologic-malignancies-438
https://cea.digitellinc.com/p/s/session-choice-page-439
https://cea.digitellinc.com/p/s/non-accredited-presentation-theater-calquence-a-btki-for-the-treatment-of-cllsll-with-updated-clinical-trial-data-and-tablet-formulation-440
https://cea.digitellinc.com/p/s/lung-cancer-441
https://cea.digitellinc.com/p/s/gastrointestinal-malignancies-442
https://cea.digitellinc.com/p/s/melanoma-and-other-skin-cancers-plus-closing-remarks-443
https://cea.digitellinc.com/p/cf/soho-houston-tx-446
https://cea.digitellinc.com/p/s/mantle-cell-lymphoma-novel-therapeutic-strategies-using-the-new-generation-of-btk-inhibitors-447
https://cea.digitellinc.com/p/cf/mood-disorders-summit-scottsdale-az-450
https://cea.digitellinc.com/p/s/opening-remarks-and-new-vs-old-debate-on-antidepressant-treatment-options-451
https://cea.digitellinc.com/p/s/session-choice-page-452
https://cea.digitellinc.com/p/s/clinical-perspectives-on-a-treatment-option-for-bipolar-depression-bipolar-i-and-ii-453
https://cea.digitellinc.com/p/s/addressing-unmet-needs-in-mdd-the-evolving-role-of-digital-therapeutics-454
https://cea.digitellinc.com/p/s/individualizing-mdd-treatment-through-augmentation-455
https://cea.digitellinc.com/p/s/session-choice-page-456
https://cea.digitellinc.com/p/s/the-efficacy-and-safety-profile-of-an-adjunctive-therapy-for-adult-patients-with-major-depressive-disorder-mdd-457
https://cea.digitellinc.com/p/s/differential-diagnosis-and-management-of-manic-states-458
https://cea.digitellinc.com/p/s/suicide-prevention-and-intervention-in-adolescents-459
https://cea.digitellinc.com/p/s/opening-remarks-and-all-mixed-up-clarifying-the-management-of-mixed-episodes-460
https://cea.digitellinc.com/p/s/session-choice-page-461
https://cea.digitellinc.com/p/s/an-established-therapy-for-treatment-resistant-depression-trd-in-adults-462
https://cea.digitellinc.com/p/s/mitigating-tardive-dyskinesia-in-aging-patients-with-mood-disorders-463
https://cea.digitellinc.com/p/s/the-future-is-coming-integration-of-psychedelic-assisted-therapy-into-practice-464
https://cea.digitellinc.com/p/s/session-choice-page-465
https://cea.digitellinc.com/p/s/a-clinical-overview-of-vraylar-r-adjunctive-treatment-for-major-depressive-disorder-in-adults-466
https://cea.digitellinc.com/p/s/difficult-to-treat-depression-a-focus-on-neuromodulation-strategies-467
https://cea.digitellinc.com/p/s/are-you-in-the-mood-to-escape-a-mood-disorder-escape-room-468
https://cea.digitellinc.com/p/cf/cea-hfsa-meeting-cleveland-oh-471
https://cea.digitellinc.com/p/s/striking-a-balance-managing-hyperkalemia-in-heart-failure-patients-with-chronic-kidney-disease-472
https://cea.digitellinc.com/p/cf/cea-hot-topics-475
https://cea.digitellinc.com/p/s/opening-remarks-and-the-future-of-ai-in-neurology-a-fireside-chat-476
https://cea.digitellinc.com/p/s/session-choice-477
https://cea.digitellinc.com/p/s/moving-forward-an-informed-approach-to-the-diagnosis-and-treatment-of-tardive-dyskinesia-478
https://cea.digitellinc.com/p/s/advances-in-multiple-sclerosis-care-diagnosis-and-treatment-479
https://cea.digitellinc.com/p/s/the-changing-landscape-of-huntingtons-disease-treatment-480
https://cea.digitellinc.com/p/s/navigating-treatment-and-the-transition-journey-to-adulthood-for-patients-with-sma-481
https://cea.digitellinc.com/p/s/the-power-of-prevention-cgrp-targeted-agents-for-migraine-and-closing-remarks-482
https://cea.digitellinc.com/p/cf/id-week-boston-ma-485
https://cea.digitellinc.com/p/s/modern-approaches-to-cmv-prevention-in-solid-organ-transplant-recipients-488
https://cea.digitellinc.com/p/s/breaking-down-barriers-dialogues-on-optimizing-engagement-in-hiv-care-489
https://cea.digitellinc.com/p/s/clinical-case-studies-in-nontuberculous-mycobacterial-lung-disease-expert-insights-on-best-practices-490
https://cea.digitellinc.com/p/s/the-x-factor-following-the-science-to-confront-mdr-dtr-and-xdr-gram-negative-infections-491
https://cea.digitellinc.com/p/s/paradigm-shift-in-microbiome-restoration-for-cdi-defining-the-role-of-live-biotherapeutic-products-492
https://cea.digitellinc.com/p/cf/amcp-nexus-orlando-fl-493
https://cea.digitellinc.com/p/s/the-evolving-understanding-of-iga-nephropathy-implications-of-new-treatment-for-managed-care-pharmacy-professionals-494
https://cea.digitellinc.com/p/cf/fmx-satellite-497
https://cea.digitellinc.com/p/s/identification-and-management-of-bipolar-depression-498
https://cea.digitellinc.com/p/s/ready-set-vaccinate-clinical-implementation-of-rsv-vaccination-for-older-adults-499
https://cea.digitellinc.com/p/s/uncomplicated-doesnt-mean-easy-recognizing-the-burden-and-preventing-treatment-failure-of-uncomplicated-utis-500
https://cea.digitellinc.com/p/cf/aasld-503
https://cea.digitellinc.com/p/s/time-to-move-the-goalpost-examing-strategies-to-advance-hbv-management-504
https://cea.digitellinc.com/p/cf/sabcs-507
https://cea.digitellinc.com/p/s/next-generation-endocrine-therapies-opportunities-in-er-plus-her2-breast-cancer-care-508
https://cea.digitellinc.com/p/cf/psychopharm-update-511
https://cea.digitellinc.com/p/s/opening-remarks-and-debate-new-vs-old-mechanisms-of-action-in-the-treatment-of-psychotic-disorders-512
https://cea.digitellinc.com/p/s/clinical-perspectives-on-a-treatment-option-for-bipolar-depression-bipolar-i-and-ii-513
https://cea.digitellinc.com/p/s/addressing-the-complexities-of-tardive-dyskinesia-treatment-in-older-adults-a-pharmacologic-perspective-514
https://cea.digitellinc.com/p/s/advances-in-narcolepsy-treatment-515
https://cea.digitellinc.com/p/s/a-focused-approach-to-the-management-of-hallucinations-and-delusions-associated-with-parkinsons-disease-psychosis-516
https://cea.digitellinc.com/p/s/augmentation-in-mdd-using-pharmacology-to-guide-treatment-517
https://cea.digitellinc.com/p/s/the-psychopharmacology-of-psychedelics-and-closing-remarks-518
https://cea.digitellinc.com/p/s/opening-remarks-and-treatment-of-bipolar-depression-pharmacology-based-individualization-519
https://cea.digitellinc.com/p/s/an-established-therapy-for-treatment-resistant-depression-trd-in-adults-520
https://cea.digitellinc.com/p/s/opioid-rems-workshop-applying-best-practices-in-pain-management-delivering-holistic-patient-centered-care-to-minimize-health-disparities-and-adverse-opioid-outcomes-521
https://cea.digitellinc.com/p/s/moving-targets-novel-mechanisms-for-the-treatment-of-mdd-522
https://cea.digitellinc.com/p/s/navigating-the-complexities-of-schizophrenia-treatment-from-challenges-to-tailored-solutions-and-closing-remarks-523
https://cea.digitellinc.com/p/cf/ash-526
https://cea.digitellinc.com/p/s/applying-the-latest-evidence-and-nccn-guideline-recommendations-in-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-527
https://cea.digitellinc.com/p/s/a-master-class-in-personalized-myelofibrosis-care-applying-new-evidence-and-novel-therapeutic-strategies-to-improve-outcomes-528
https://cea.digitellinc.com/p/s/an-mcl-quiz-game-experts-review-new-and-emerging-therapies-to-optimize-clinical-outcomes-529
https://cea.digitellinc.com/p/s/an-expert-guide-to-whats-new-and-whats-next-for-novel-targeted-therapies-in-relapsedrefractory-follicular-lymphoma-530
https://cea.digitellinc.com/p/s/advances-in-autoimmune-hemolytic-anemia-targeting-the-complement-cascade-in-cold-agglutinin-disease-531
https://cea.digitellinc.com/p/s/al-amyloidosis-advancements-and-future-trends-on-diagnosis-and-individualized-treatment-approaches-532
https://cea.digitellinc.com/p/cf/cea-parp-inhibitor-combination-approaches-in-prostate-125-535
https://cea.digitellinc.com/p/s/parp-inhibitor-combination-approaches-in-prostate-cancer-interpretation-of-clinical-findings-and-regulatory-approvals-536
https://cea.digitellinc.com/p/cf/applexus-conference-feb-3-539
https://cea.digitellinc.com/p/s/welcome-and-leukemias-and-mds-insights-from-ash-2023-540
https://cea.digitellinc.com/p/s/session-choice-page-541
https://cea.digitellinc.com/p/s/nonaccredited-presentation-theater-long-term-clinical-trial-results-for-a-btki-in-the-treatment-of-cllsll-542
https://cea.digitellinc.com/p/s/lymphoma-i-cll-and-mcl-insights-from-ash-2023-543
https://cea.digitellinc.com/p/s/session-choice-page-544
https://cea.digitellinc.com/p/s/nonaccredited-presentation-theater-polycythemia-vera-clinical-case-discussion-when-to-intervene-with-jakafi-r-ruxolitinib-545
https://cea.digitellinc.com/p/s/lymphoma-ii-dlbcl-fl-chl-and-ptcl-insights-from-ash-2023-and-closing-remarks-546
https://cea.digitellinc.com/p/cf/applexus-conference-feb-10-549
https://cea.digitellinc.com/p/s/welcome-and-non-malignant-hematology-insights-from-ash-2023-550
https://cea.digitellinc.com/p/s/session-choice-page-551
https://cea.digitellinc.com/p/s/nonaccredited-presentation-theater-the-role-of-apps-in-maximizing-patient-outcomes-with-darzalex-and-darzalex-faspro-plus-rd-in-patients-with-newly-diagnosed-transplant-ineligible-multiple-myeloma-552
https://cea.digitellinc.com/p/s/mpns-insights-from-ash-2023-553
https://cea.digitellinc.com/p/s/session-choice-page-554
https://cea.digitellinc.com/p/s/nonaccredited-presentation-theater-a-discussion-of-a-real-world-patient-case-of-chronic-gvhd-intervene-at-the-first-signs-of-initial-systemic-treatment-failure-555
https://cea.digitellinc.com/p/s/multiple-myeloma-insights-from-ash-2023-and-closing-remarks-556
https://cea.digitellinc.com/p/cf/applexus-conference-mar-559
https://cea.digitellinc.com/p/s/session-choice-page-560
https://cea.digitellinc.com/p/s/nonaccredited-presentation-theater-lonsurf-r-plus-bevacizumab-for-the-treatment-of-3l-metastatic-colorectal-cancer-561
https://cea.digitellinc.com/p/s/welcome-and-a-review-of-key-crc-studies-from-the-2024-asco-gastrointestinal-cancers-symposium-562
https://cea.digitellinc.com/p/s/session-choice-page-563
https://cea.digitellinc.com/p/s/nonaccredited-pt-pemazyre-r-pemigatinib-the-first-fda-approved-treatment-for-adults-wpreviously-treated-unresectable-locally-advanced-or-metastatic-cholangiocarcinoma-wan-fgfr2-fusion-or-rearrangement-564
https://cea.digitellinc.com/p/s/a-review-of-key-hepatobiliary-studies-from-the-2024-asco-gastrointestinal-cancers-symposium-and-qualitative-assessment-of-and-commitment-to-practice-change-565
https://cea.digitellinc.com/p/s/a-review-of-key-hepatobiliary-studies-from-the-2024-asco-gastrointestinal-cancers-symposium-and-qualitative-assessment-of-and-commitment-to-practice-change-566
https://cea.digitellinc.com/p/cf/apha-569
https://cea.digitellinc.com/p/s/standing-order-for-success-overcoming-barriers-to-rsv-vaccination-in-pharmacy-practice-570
https://cea.digitellinc.com/p/cf/uscap-2024-573
https://cea.digitellinc.com/p/s/addressing-key-questions-expert-insights-to-guide-pathologist-informed-clinical-decisions-in-her2-expressing-or-amplified-solid-tumors-574
https://cea.digitellinc.com/p/cf/nppa-psychiatry-update-series-apr-2024-577
https://cea.digitellinc.com/p/s/silent-struggles-bridging-gaps-in-ptsd-care-for-a-holistic-healing-journey-and-opening-remarks-578
https://cea.digitellinc.com/p/s/session-choice-page-579
https://cea.digitellinc.com/p/s/clinical-perspectives-on-a-treatment-option-for-bipolar-depression-bipolar-i-and-ii-580
https://cea.digitellinc.com/p/s/charting-paths-evidence-based-decisions-in-mdd-treatment-beyond-the-first-line-581
https://cea.digitellinc.com/p/s/insights-into-tardive-dyskinesia-in-an-aging-population-582
https://cea.digitellinc.com/p/s/session-choice-page-583
https://cea.digitellinc.com/p/s/beyond-the-baseline-a-comprehensive-approach-to-diagnosis-and-treatment-of-tardive-dyskinesia-584
https://cea.digitellinc.com/p/s/restoring-serenity-evidence-based-strategies-for-managing-agitation-in-alzheimers-disease-585
https://cea.digitellinc.com/p/s/substance-use-disorders-and-closing-remarks-586
https://cea.digitellinc.com/p/cf/md-psychiatry-update-series-apr-2024-589
https://cea.digitellinc.com/p/s/silent-struggles-bridging-gaps-in-ptsd-care-for-a-holistic-healing-journey-590
https://cea.digitellinc.com/p/s/opening-remarks-and-restoring-serenity-evidence-based-strategies-for-managing-agitation-in-alzheimers-disease-591
https://cea.digitellinc.com/p/s/session-choice-page-593
https://cea.digitellinc.com/p/s/beyond-the-baseline-a-comprehensive-approach-to-diagnosis-and-treatment-of-tardive-dyskinesia-594
https://cea.digitellinc.com/p/s/beyond-the-first-line-navigating-the-crossroads-of-mdd-treatment-switching-and-augmentation-strategies-595
https://cea.digitellinc.com/p/s/managing-pain-and-opioid-use-disorder-with-consideration-for-both-physical-and-psychiatric-manifestations-and-closing-remarks-596
https://cea.digitellinc.com/p/cf/aspho-apr-599
https://cea.digitellinc.com/p/s/mastering-asparaginase-regimens-in-the-care-of-pediatric-and-aya-patients-with-acute-lymphoblastic-leukemia-600
https://cea.digitellinc.com/p/cf/acp-internal-medicine-apr-16-and-17-603
https://cea.digitellinc.com/p/cf/hopa-apr-604
https://cea.digitellinc.com/p/s/maximizing-efficacy-and-minimizing-toxicity-of-adcs-targeting-her2-her3-and-trop-2-strategies-for-oncology-pharmacists-605
https://cea.digitellinc.com/p/cf/amcp-apr-608
https://cea.digitellinc.com/p/s/beyond-barriers-managed-care-approaches-to-ensure-equitable-and-timely-access-to-bcma-directed-therapy-in-multiple-myeloma-609
https://cea.digitellinc.com/p/s/strategies-for-success-best-practices-to-optimize-shingles-vaccine-uptake-612
https://cea.digitellinc.com/p/s/easy-as-1-2-3-simplifying-rsv-vaccination-for-older-adults-613
https://cea.digitellinc.com/p/s/hot-topics-in-menopause-latest-advances-in-the-management-and-treatment-of-vms-614
https://cea.digitellinc.com/p/cf/acp-419-617
https://cea.digitellinc.com/p/s/staying-on-target-reducing-cv-risk-by-achieving-ldl-c-targets-with-statin-and-nonstatin-therapies-618
https://cea.digitellinc.com/p/cf/nppa-psychiatry-update-series-apr-26-2024-621
https://cea.digitellinc.com/p/s/silent-struggles-bridging-gaps-in-ptsd-care-for-a-holistic-healing-journey-and-opening-remarks-622
https://cea.digitellinc.com/p/s/charting-paths-evidence-based-decisions-in-mdd-treatment-beyond-the-first-line-623
https://cea.digitellinc.com/p/s/insights-into-tardive-dyskinesia-in-an-aging-population-624
https://cea.digitellinc.com/p/s/session-choice-page-625
https://cea.digitellinc.com/p/s/beyond-the-baseline-a-comprehensive-approach-to-diagnosis-and-treatment-of-tardive-dyskinesia-626
https://cea.digitellinc.com/p/s/restoring-serenity-evidence-based-strategies-for-managing-agitation-in-alzheimers-disease-627
https://cea.digitellinc.com/p/s/substance-use-disorders-and-closing-remarks-628
https://cea.digitellinc.com/p/cf/md-psychiatry-update-series-apr-27-2024-631
https://cea.digitellinc.com/p/s/silent-struggles-bridging-gaps-in-ptsd-care-for-a-holistic-healing-journey-and-opening-remarks-632
https://cea.digitellinc.com/p/s/restoring-serenity-evidence-based-strategies-for-managing-agitation-in-alzheimers-disease-633
https://cea.digitellinc.com/p/s/approaching-weight-loss-and-metabolic-issues-in-psychiatry-634
https://cea.digitellinc.com/p/s/session-choice-page-635
https://cea.digitellinc.com/p/s/beyond-the-baseline-a-comprehensive-approach-to-diagnosis-and-treatment-of-tardive-dyskinesia-636
https://cea.digitellinc.com/p/s/beyond-the-first-line-navigating-the-crossroads-of-mdd-treatment-switching-and-augmentation-strategies-637
https://cea.digitellinc.com/p/s/managing-pain-and-opioid-use-disorder-with-consideration-for-both-physical-and-psychiatric-manifestations-and-closing-remarks-638
https://cea.digitellinc.com/p/cf/psychiatry-summit-2024-641
https://cea.digitellinc.com/p/s/opening-remarks-and-medical-and-mental-health-issues-in-gender-affirming-hormonal-treatments-for-transgender-and-gender-diverse-patients-642
https://cea.digitellinc.com/p/s/navigating-a-new-era-of-targeted-treatments-for-postpartum-depression-643
https://cea.digitellinc.com/p/s/shadows-of-wellness-residual-symptoms-in-major-depressive-disorder-644
https://cea.digitellinc.com/p/s/calming-the-storm-understanding-and-managing-agitation-in-alzheimers-disease-645
https://cea.digitellinc.com/p/s/decoding-complexity-best-practices-in-identifying-and-managing-bipolar-depression-with-dsm-5-tr-specifiers-and-closing-remarks-646
https://cea.digitellinc.com/p/s/opening-remarks-and-beyond-the-breaking-point-evaluation-and-management-of-patients-in-crisis-647
https://cea.digitellinc.com/p/s/catatonia-from-psychopathology-to-neurobiology-648
https://cea.digitellinc.com/p/s/cultivating-inclusivity-paving-the-path-to-improved-diversity-in-clinical-trials-649
https://cea.digitellinc.com/p/s/navigating-the-frontier-of-schizophrenia-treatment-unveiling-innovations-and-ensuring-patient-well-being-650
https://cea.digitellinc.com/p/s/breaking-ground-exploring-the-horizon-of-emerging-treatments-for-ptsd-and-closing-remarks-651
https://cea.digitellinc.com/p/cf/applexus-hot-topics-654
https://cea.digitellinc.com/p/s/welcome-and-advances-in-targeted-therapeutics-for-biliary-tract-cancer-655
https://cea.digitellinc.com/p/s/bcma-immunotherapy-bispecific-platforms-and-cd38-antibodies-in-myeloma-optimizing-treatment-and-enhancing-access-656
https://cea.digitellinc.com/p/s/redefining-precision-therapeutics-in-hematologic-malignancies-current-practice-and-next-questions-on-bispecific-antibodies-657
https://cea.digitellinc.com/p/s/next-generation-care-for-patients-with-bladder-cancer-658
https://cea.digitellinc.com/p/s/clinical-updates-on-non-covalent-btk-inhibitors-in-cll-and-mcl-and-closing-remarks-659
https://cea.digitellinc.com/p/cf/asco-662
https://cea.digitellinc.com/p/s/caring-for-patients-with-cancer-in-a-post-covid-world-expert-guidance-on-the-latest-data-and-therapeutic-advances-to-mitigate-infection-risk-663
https://cea.digitellinc.com/p/s/cancer-conversations-on-the-expanding-therapeutic-landscape-for-cdk46-inhibitors-in-hr-positiveher2-negative-breast-cancer-664
https://cea.digitellinc.com/p/s/immunotherapy-in-hcc-improving-outcomes-across-the-disease-continuum-665
https://cea.digitellinc.com/p/s/myelofibrosis-expert-roundtable-state-of-the-art-clinical-advances-and-therapeutic-strategies-from-jak-inhibition-into-the-future-666
https://cea.digitellinc.com/p/s/applying-nccn-guidelines-for-the-treatment-of-cllsll-in-clinical-practice-the-right-agent-for-the-right-patient-at-the-right-time-667
https://cea.digitellinc.com/p/s/expert-perspectives-on-the-evolving-treatment-of-egfr-mutated-advanced-and-metastatic-nsclc-668
https://cea.digitellinc.com/p/s/targeted-therapies-in-advanced-biliary-tract-cancer-practical-strategies-in-a-changing-therapeutic-landscape-669
https://cea.digitellinc.com/p/s/next-generation-therapeutics-for-hr-plus-her2-breast-cancer-spotlight-on-serds-670
https://cea.digitellinc.com/p/cf/ascp-673
https://cea.digitellinc.com/p/s/cultivating-inclusivity-paving-the-path-to-improved-diversity-in-clinical-trials-674
https://cea.digitellinc.com/p/cf/nppa-psychiatry-update-series-jun-2024-677
https://cea.digitellinc.com/p/s/opening-remarks-and-casting-a-wide-net-identifying-and-treating-tardive-dyskinesia-in-diverse-patient-populations-678
https://cea.digitellinc.com/p/s/charting-paths-evidence-based-decisions-in-mdd-treatment-beyond-the-first-line-679
https://cea.digitellinc.com/p/s/overdose-prevention-and-harm-reduction-strategies-for-advanced-practice-providers-680
https://cea.digitellinc.com/p/s/beyond-the-baseline-a-comprehensive-approach-to-diagnosis-and-treatment-of-tardive-dyskinesia-681
https://cea.digitellinc.com/p/s/restoring-serenity-evidence-based-strategies-for-managing-agitation-in-alzheimers-disease-682
https://cea.digitellinc.com/p/s/silent-struggles-bridging-gaps-in-ptsd-care-for-a-holistic-healing-journey-and-closing-remarks-683
https://cea.digitellinc.com/p/cf/md-psychiatry-update-series-jun-2024-686
https://cea.digitellinc.com/p/s/opening-remarks-and-silent-struggles-bridging-gaps-in-ptsd-care-for-a-holistic-healing-journey-689
https://cea.digitellinc.com/p/s/restoring-serenity-evidence-based-strategies-for-managing-agitation-in-alzheimers-disease-690
https://cea.digitellinc.com/p/s/unlocking-potential-glp-1-agonists-in-psychiatry-promise-pitfalls-and-perspectives-691
https://cea.digitellinc.com/p/s/beyond-the-baseline-a-comprehensive-approach-to-diagnosis-and-treatment-of-tardive-dyskinesia-692
https://cea.digitellinc.com/p/s/beyond-the-first-line-navigating-the-crossroads-of-mdd-treatment-switching-and-augmentation-strategies-693
https://cea.digitellinc.com/p/s/managing-pain-and-opioid-use-disorder-with-consideration-for-both-physical-and-psychiatric-manifestations-and-closing-remarks-694
https://cea.digitellinc.com/p/s/session-choice-page-695
https://cea.digitellinc.com/p/s/session-choice-page-696
https://cea.digitellinc.com/p/cf/best-of-asco-2024-697
https://cea.digitellinc.com/p/s/welcome-and-conference-to-clinic-hematologic-malignancies-698
https://cea.digitellinc.com/p/s/session-choice-page-699
https://cea.digitellinc.com/p/s/nonaccredited-presentation-theater-treatment-and-monitoring-of-patients-with-cml-and-ph-plus-all-700
https://cea.digitellinc.com/p/s/conference-to-clinic-breast-cancer-701
https://cea.digitellinc.com/p/s/session-choice-page-702
https://cea.digitellinc.com/p/s/nonaccredited-presentation-theater-come-see-the-latest-clinical-evidence-for-enhertu-r-fam-trastuzumab-deruxtecan-nxki-703
https://cea.digitellinc.com/p/s/conference-to-clinic-lung-cancer-704
https://cea.digitellinc.com/p/s/conference-to-clinic-skin-cancer-705
https://cea.digitellinc.com/p/s/conference-to-clinic-genitourinary-cancer-and-closing-remarks-706
https://cea.digitellinc.com/p/cf/ada-symposium-jun-2024-709
https://cea.digitellinc.com/p/s/striking-a-balance-the-role-of-glucagon-agonism-to-improve-obesity-and-metabolic-care-710
https://cea.digitellinc.com/p/cf/applexus-aug-2024-713
https://cea.digitellinc.com/p/s/welcome-and-improving-outcomes-in-patients-with-high-risk-breast-cancer-expert-guidance-and-team-training-for-hr-positiveher2-negative-disease-714
https://cea.digitellinc.com/p/s/session-choice-page-715
https://cea.digitellinc.com/p/s/nonaccredited-presentation-theater-guidance-for-management-of-truqap-r-adverse-reactions-716
https://cea.digitellinc.com/p/s/sequencing-treatment-in-her2-positive-metastatic-breast-cancer-and-closing-remarks-717
https://cea.digitellinc.com/p/cf/nppa-psychiatry-update-series-jul-2024-720
https://cea.digitellinc.com/p/s/opening-remarks-and-silent-struggles-bridging-gaps-in-ptsd-care-for-a-holistic-healing-journey-721
https://cea.digitellinc.com/p/s/charting-paths-evidence-based-decisions-in-mdd-treatment-beyond-the-first-line-722
https://cea.digitellinc.com/p/s/casting-a-wide-net-identifying-and-treating-tardive-dyskinesia-in-diverse-patient-populations-723
https://cea.digitellinc.com/p/s/session-choice-724
https://cea.digitellinc.com/p/s/beyond-the-baseline-a-comprehensive-approach-to-diagnosis-and-treatment-of-tardive-dyskinesia-725
https://cea.digitellinc.com/p/s/restoring-serenity-evidence-based-strategies-for-managing-agitation-in-alzheimers-disease-726
https://cea.digitellinc.com/p/s/overdose-prevention-and-harm-reduction-strategies-for-advanced-practice-providers-and-closing-remarks-727
https://cea.digitellinc.com/p/cf/md-psychiatry-update-series-jul-2024-730
https://cea.digitellinc.com/p/s/opening-remarks-and-silent-struggles-bridging-gaps-in-ptsd-care-for-a-holistic-healing-journey-733
https://cea.digitellinc.com/p/s/restoring-serenity-evidence-based-strategies-for-managing-agitation-in-alzheimers-disease-734
https://cea.digitellinc.com/p/s/unlocking-potential-glp-1-agonists-in-psychiatry-promise-pitfalls-and-perspectives-735
https://cea.digitellinc.com/p/s/session-choice-page-736
https://cea.digitellinc.com/p/s/beyond-the-baseline-a-comprehensive-approach-to-diagnosis-and-treatment-of-tardive-dyskinesia-737
https://cea.digitellinc.com/p/s/beyond-the-first-line-navigating-the-crossroads-of-mdd-treatment-switching-and-augmentation-strategies-738
https://cea.digitellinc.com/p/s/managing-pain-and-opioid-use-disorder-with-consideration-for-both-physical-and-psychiatric-manifestations-and-closing-remarks-739
https://cea.digitellinc.com/p/cf/elevate-derm-jul-2024-740
https://cea.digitellinc.com/p/s/are-you-ready-to-elevate-your-knowledge-integrating-aad-guideline-updates-to-optimize-patient-care-in-atopic-dermatitis-741
https://cea.digitellinc.com/p/cf/nppa-psychiatry-update-series-aug-2024-744
https://cea.digitellinc.com/p/cf/md-psychiatry-update-series-aug-2024-745
https://cea.digitellinc.com/p/s/opening-remarks-and-casting-a-wide-net-identifying-and-treating-tardive-dyskinesia-in-diverse-patient-populations-746
https://cea.digitellinc.com/p/s/restoring-serenity-evidence-based-strategies-for-managing-agitation-in-alzheimers-disease-747
https://cea.digitellinc.com/p/s/silent-struggles-bridging-gaps-in-ptsd-care-for-a-holistic-healing-journey-748
https://cea.digitellinc.com/p/s/session-choice-749
https://cea.digitellinc.com/p/s/beyond-the-baseline-a-comprehensive-approach-to-diagnosis-and-treatment-of-tardive-dyskinesia-750
https://cea.digitellinc.com/p/s/charting-paths-evidence-based-decisions-in-mdd-treatment-beyond-the-first-line-751
https://cea.digitellinc.com/p/s/overdose-prevention-and-harm-reduction-strategies-for-advanced-practice-providers-and-closing-remarks-752
https://cea.digitellinc.com/p/s/opening-remarks-and-silent-struggles-bridging-gaps-in-ptsd-care-for-a-holistic-healing-journey-753
https://cea.digitellinc.com/p/s/restoring-serenity-evidence-based-strategies-for-managing-agitation-in-alzheimers-disease-754
https://cea.digitellinc.com/p/s/unlocking-potential-glp-1-agonists-in-psychiatry-promise-pitfalls-and-perspectives-755
https://cea.digitellinc.com/p/s/session-choice-page-756
https://cea.digitellinc.com/p/s/beyond-the-baseline-a-comprehensive-approach-to-diagnosis-and-treatment-of-tardive-dyskinesia-757
https://cea.digitellinc.com/p/s/beyond-the-first-line-navigating-the-crossroads-of-mdd-treatment-switching-and-augmentation-strategies-758
https://cea.digitellinc.com/p/s/managing-pain-and-opioid-use-disorder-with-consideration-for-both-physical-and-psychiatric-manifestations-and-closing-remarks-759
https://cea.digitellinc.com/p/cf/gapna-pt-sept-2024-764
https://cea.digitellinc.com/p/s/management-of-tardive-dyskinesia-with-considerations-for-special-populations-helping-our-patients-age-well-765
https://cea.digitellinc.com/p/cf/mood-disorders-sept-2024-768
https://cea.digitellinc.com/p/s/opening-remarks-and-understanding-ai-in-mental-health-and-its-impact-on-mood-disorders-769
https://cea.digitellinc.com/p/s/session-choice-page-770
https://cea.digitellinc.com/p/s/the-patient-journey-through-bipolar-i-depression-including-the-presence-of-mixed-features-771
https://cea.digitellinc.com/p/s/tackling-tardive-dyskinesia-in-older-patients-with-mood-disorders-772
https://cea.digitellinc.com/p/s/beyond-the-surface-exploring-inflammation-as-a-target-for-mood-disorder-treatments-773
https://cea.digitellinc.com/p/s/session-choice-page-774
https://cea.digitellinc.com/p/s/beyond-the-baseline-a-comprehensive-approach-to-diagnosis-and-treatment-of-tardive-dyskinesia-product-theater-congress-program-description-775
https://cea.digitellinc.com/p/s/from-diagnosis-to-empowerment-patient-centered-strategies-for-optimizing-management-of-bipolar-i-disorder-776
https://cea.digitellinc.com/p/s/session-choice-page-777
https://cea.digitellinc.com/p/s/treating-mdd-a-rapid-acting-oral-antidepressant-with-multimodal-activity-778
https://cea.digitellinc.com/p/s/do-novel-mechanisms-for-depression-treatment-herald-brighter-days-ahead-for-patients-with-residual-anhedonia-and-closing-remarks-779
https://cea.digitellinc.com/p/s/openings-remarks-and-a-person-centered-approach-to-crisis-de-escalation-in-patients-with-mood-disorders-780
https://cea.digitellinc.com/p/s/session-choice-page-781
https://cea.digitellinc.com/p/s/a-clinical-overview-of-vraylar-managing-the-full-spectrum-of-bipolar-i-disorder-in-adults-782
https://cea.digitellinc.com/p/s/empowering-recovery-targeted-therapies-for-postpartum-depression-783
https://cea.digitellinc.com/p/s/addressing-the-complexities-of-bipolar-depression-with-dsm-specifiers-784
https://cea.digitellinc.com/p/s/session-choice-page-785
https://cea.digitellinc.com/p/s/long-term-strategies-in-treatment-resistant-depression-786
https://cea.digitellinc.com/p/s/clinical-crossroads-navigating-mdd-treatment-challenges-through-real-world-cases-787
https://cea.digitellinc.com/p/s/unlocking-hope-psychedelics-in-the-treatment-of-major-depressive-disorder-and-closing-remarks-788
https://cea.digitellinc.com/p/cf/medx-pa-sept-2024-791
https://cea.digitellinc.com/p/cf/medx-nj-sept-2024-792
https://cea.digitellinc.com/p/s/opening-remarks-and-clinical-excellence-in-ptsd-care-aligning-real-world-practice-to-guidelines-793
https://cea.digitellinc.com/p/s/across-the-divide-optimal-approaches-for-hpv-vaccination-among-diverse-populations-794
https://cea.digitellinc.com/p/s/session-choice-page-795
https://cea.digitellinc.com/p/s/attention-on-mash-the-hepatic-manifestation-of-the-metabolic-syndrome-non-cme-educational-session-managed-by-mdoutlook-clinical-care-solutions-a-cea-company-796
https://cea.digitellinc.com/p/s/recognizing-and-responding-to-children-at-risk-suspected-child-abuse-and-neglect-797
https://cea.digitellinc.com/p/s/mastering-menopause-management-hot-updates-for-primary-care-798
https://cea.digitellinc.com/p/s/head-to-toe-pain-management-identifying-and-managing-patients-with-pain-to-minimize-adverse-outcomes-799
https://cea.digitellinc.com/p/s/session-choice-page-800
https://cea.digitellinc.com/p/s/tailoring-care-for-weight-and-cv-risk-in-your-appropriate-patients-non-cme-educational-session-managed-by-mdoutlook-clinical-care-solutions-a-cea-company-801
https://cea.digitellinc.com/p/s/going-for-gold-in-copd-optimizing-diagnosis-and-management-in-primary-care-to-enhance-patient-outcomes-802
https://cea.digitellinc.com/p/s/easing-the-agitation-burden-evidence-based-approaches-to-addressing-agitation-associated-with-dementia-due-to-alzheimers-disease-and-closing-remarks-803
https://cea.digitellinc.com/p/s/welcome-and-mastering-menopause-management-hot-updates-for-primary-care-808
https://cea.digitellinc.com/p/s/across-the-divide-optimal-approaches-for-hpv-vaccination-among-diverse-populations-809
https://cea.digitellinc.com/p/s/clinical-excellence-in-ptsd-care-aligning-real-world-practice-to-guidelines-810
https://cea.digitellinc.com/p/s/easing-the-agitation-burden-evidence-based-approaches-to-addressing-agitation-associated-with-dementia-due-to-alzheimers-disease-811
https://cea.digitellinc.com/p/s/understanding-mash-exploring-the-role-of-metabolic-dysfunction-in-an-often-silent-and-progressive-liver-disease-non-cme-educational-session-managed-by-mdoutlook-clinical-care-solutions-a-cea-company-812
https://cea.digitellinc.com/p/s/head-to-toe-pain-management-identifying-and-managing-patients-with-pain-to-minimize-adverse-outcomes-and-closing-remarks-813
https://cea.digitellinc.com/p/s/session-choice-page-814
https://cea.digitellinc.com/p/s/elevating-mdd-care-integration-of-prescription-digital-therapeutics-into-mdd-treatment-815
https://cea.digitellinc.com/p/cf/hot-topics-in-neurology-oct-2024-816
https://cea.digitellinc.com/p/s/opening-remarks-and-ready-set-act-empowering-patients-with-seizure-action-plans-817
https://cea.digitellinc.com/p/s/session-choice-818
https://cea.digitellinc.com/p/s/advancements-in-rett-syndrome-rtt-care-819
https://cea.digitellinc.com/p/s/gut-microbiome-in-neurologic-health-820
https://cea.digitellinc.com/p/s/session-choice-821
https://cea.digitellinc.com/p/s/managing-hyperkinetic-movement-disorders-from-symptoms-and-impacts-to-approved-treatment-822
https://cea.digitellinc.com/p/s/agitation-psychosis-and-other-behavioral-symptoms-in-alzheimers-disease-823
https://cea.digitellinc.com/p/s/early-detection-better-care-migraine-diagnosis-and-treatment-824
https://cea.digitellinc.com/p/s/stepping-stones-to-stability-a-closer-look-at-identifying-and-treating-huntingtons-disease-chorea-and-closing-remarks-825
https://cea.digitellinc.com/p/cf/aap-satellite-sept-2024-828
https://cea.digitellinc.com/p/s/are-you-the-hpv-vaccine-champion-advanced-strategies-for-uptake-and-cancer-prevention-in-your-pediatric-practice-829
https://cea.digitellinc.com/p/cf/cco-satellite-at-fmx-sept-2024-832
https://cea.digitellinc.com/p/s/elevating-patient-care-in-mdd-switching-and-augmentation-strategies-833
https://cea.digitellinc.com/p/cf/psych-update-nppa-oct-2024-836
https://cea.digitellinc.com/p/s/opening-remarks-and-restoring-serenity-evidence-based-strategies-for-managing-agitation-in-alzheimers-disease-839
https://cea.digitellinc.com/p/s/session-choice-840
https://cea.digitellinc.com/p/s/exploring-the-role-of-an-adjunctive-therapy-for-patients-with-major-depressive-disorder-841
https://cea.digitellinc.com/p/s/charting-paths-evidence-based-decisions-in-mdd-treatment-beyond-the-first-line-842
https://cea.digitellinc.com/p/s/casting-a-wide-net-identifying-and-treating-tardive-dyskinesia-in-diverse-patient-populations-843
https://cea.digitellinc.com/p/s/silent-struggles-bridging-gaps-in-ptsd-care-for-a-holistic-healing-journey-844
https://cea.digitellinc.com/p/s/overdose-prevention-and-harm-reduction-strategies-for-advanced-practice-providers-and-closing-remarks-845
https://cea.digitellinc.com/p/cf/psych-update-md-oct-2024-846
https://cea.digitellinc.com/p/s/opening-remarks-and-silent-struggles-bridging-gaps-in-ptsd-care-for-a-holistic-healing-journey-847
https://cea.digitellinc.com/p/s/a-holistic-approach-to-managing-opioid-use-disorder-848
https://cea.digitellinc.com/p/s/restoring-serenity-evidence-based-strategies-for-managing-agitation-in-alzheimers-disease-849
https://cea.digitellinc.com/p/s/unlocking-potential-glp-1-agonists-in-psychiatry-promise-pitfalls-and-perspectives-850
https://cea.digitellinc.com/p/s/beyond-the-first-line-navigating-the-crossroads-of-mdd-treatment-switching-and-augmentation-strategies-and-closing-remarks-851
https://cea.digitellinc.com/p/cf/ash-dec-2024-854
https://cea.digitellinc.com/p/s/an-interactive-case-based-review-of-chronic-lymphocytic-leukemia-experts-explore-the-latest-evidence-and-guideline-updates-855
https://cea.digitellinc.com/p/s/a-game-changer-for-follicular-lymphoma-mastering-use-of-precision-therapies-as-part-of-a-chemo-free-treatment-paradigm-856
https://cea.digitellinc.com/p/s/application-of-evolving-evidence-in-mantle-cell-lymphoma-therapeutic-strategies-using-btk-inhibitors-857
https://cea.digitellinc.com/p/cf/psych-update-nppa-nov-2024-860
https://cea.digitellinc.com/p/cf/psych-update-md-nov-2024-861
https://cea.digitellinc.com/p/s/opening-remarks-and-silent-struggles-bridging-gaps-in-ptsd-care-for-a-holistic-healing-journey-862
https://cea.digitellinc.com/p/s/session-choice-page-863
https://cea.digitellinc.com/p/s/the-patient-journey-through-bipolar-ii-depression-864
https://cea.digitellinc.com/p/s/charting-paths-evidence-based-decisions-in-mdd-treatment-beyond-the-first-line-865
https://cea.digitellinc.com/p/s/casting-a-wide-net-identifying-and-treating-tardive-dyskinesia-in-diverse-patient-populations-866
https://cea.digitellinc.com/p/s/restoring-serenity-evidence-based-strategies-for-managing-agitation-in-alzheimers-disease-867
https://cea.digitellinc.com/p/s/overdose-prevention-and-harm-reduction-strategies-for-advanced-practice-providers-868
https://cea.digitellinc.com/p/s/pioneering-pathways-new-and-emerging-agents-for-schizophrenia-and-closing-remarks-869
https://cea.digitellinc.com/p/s/opening-remarks-and-silent-struggles-bridging-gaps-in-ptsd-care-for-a-holistic-healing-journey-874
https://cea.digitellinc.com/p/s/beyond-the-first-line-navigating-the-crossroads-of-mdd-treatment-switching-and-augmentation-strategies-and-closing-remarks-875
https://cea.digitellinc.com/p/s/restoring-serenity-evidence-based-strategies-for-managing-agitation-in-alzheimers-disease-876
https://cea.digitellinc.com/p/s/unlocking-potential-glp-1-agonists-in-psychiatry-promise-pitfalls-and-perspectives-877
https://cea.digitellinc.com/p/s/a-holistic-approach-to-managing-opioid-use-disorder-878
https://cea.digitellinc.com/p/s/pioneering-pathways-new-and-emerging-agents-for-schizophrenia-and-closing-remarks-879
https://cea.digitellinc.com/p/cf/aasld-nov-2024-880
https://cea.digitellinc.com/p/s/alpha-1-antitrypsin-deficiency-are-you-overlooking-a-leading-genetic-culprit-in-liver-disease-881
https://cea.digitellinc.com/p/s/itching-for-more-improving-care-of-pruritus-in-pbc-882
https://cea.digitellinc.com/p/cf/psychopharm-dec-2024-885
https://cea.digitellinc.com/p/cf/cardio-intensive-dec-2024-886
https://cea.digitellinc.com/p/s/appreciating-the-role-of-apps-in-optimizing-gdmt-in-hf-with-sglt2-inhibitors-887
https://cea.digitellinc.com/p/s/session-choice-page-888
https://cea.digitellinc.com/p/s/tailoring-care-for-weight-and-cv-risk-in-your-appropriate-patients-non-cme-educational-session-managed-by-mdoutlookclinical-care-solutions-a-cea-company-889
https://cea.digitellinc.com/p/s/advances-in-ascvd-risk-reduction-a-focus-on-nonstatin-therapies-and-the-role-of-lpa-890
https://cea.digitellinc.com/p/s/opening-session-and-keynote-session-do-obesity-and-diabetes-mellitus-metastasize-to-the-brain-metaboptosis-and-implications-for-potential-therapeutics-in-psychiatry-893
https://cea.digitellinc.com/p/s/session-choice-894
https://cea.digitellinc.com/p/s/non-cme-educational-session-the-patient-journey-through-bipolar-ii-depression-895
https://cea.digitellinc.com/p/s/estrogen-and-mood-psychiatric-considerations-over-the-reproductive-lifecycle-896
https://cea.digitellinc.com/p/s/agitation-psychosis-and-other-behavioral-issues-in-alzheimers-dementia-897
https://cea.digitellinc.com/p/s/session-choice-898
https://cea.digitellinc.com/p/s/non-cme-educational-session-long-term-strategies-in-treatment-resistant-depression-899
https://cea.digitellinc.com/p/s/innovation-insight-how-are-novel-agents-reshaping-schizophrenias-landscape-900
https://cea.digitellinc.com/p/s/navigating-cannabis-use-in-psychiatric-populations-drug-drug-interactions-and-other-pharmacologic-considerations-and-closing-remarks-901
https://cea.digitellinc.com/p/s/opening-remarks-and-a-pharmacologic-view-of-tardive-dyskinesia-pathology-and-treatment-902
https://cea.digitellinc.com/p/s/sutures-psych-and-sobriety-tying-together-psychiatric-post-op-support-for-at-risk-patients-903
https://cea.digitellinc.com/p/s/innovative-approaches-for-ptsd-unraveling-pathophysiology-and-new-treatment-frontiers-904
https://cea.digitellinc.com/p/s/clusters-of-concerns-neurobiology-and-treatment-of-psychiatric-disorder-comorbidities-905
https://cea.digitellinc.com/p/s/iterative-psychopharmacology-how-to-decide-what-to-do-when-first-or-second-interventions-fail-906
https://cea.digitellinc.com/p/s/from-pain-to-purpose-the-intersection-of-psychiatry-pain-management-and-opioid-safety-and-closing-remarks-907
https://cea.digitellinc.com/p/cf/suo-dec-2024-910
https://cea.digitellinc.com/p/s/vital-questions-for-treatment-of-bladder-cancer-expert-insights-on-recent-and-near-future-changes-913
https://cea.digitellinc.com/p/cf/ashp-dec-2024-914
https://cea.digitellinc.com/p/s/pneumococcal-disease-prevention-integrating-the-latest-vaccine-updates-into-practice-915
https://cea.digitellinc.com/p/cf/breast-cdk46-jan-918
https://cea.digitellinc.com/p/s/individualizing-the-current-adjuvant-therapy-algorithm-for-patients-with-hr-plus-her2-ebc-919
https://cea.digitellinc.com/p/s/session-choice-920
https://cea.digitellinc.com/p/s/nonaccredited-product-theater-a-2l-treatment-option-for-hr-plus-her2-abc-or-mbc-with-pik3ca-akt1-or-pten-alterations-following-progression-on-or-after-et-cdk46i-921
https://cea.digitellinc.com/p/s/individualizing-therapy-for-patients-with-hr-plus-her2-mbc-922
https://cea.digitellinc.com/p/s/managing-aes-with-cdk46-inhibitors-to-promote-adherence-and-persistence-to-oral-therapy-in-your-practice-923
https://cea.digitellinc.com/p/cf/clinic-highlights-jan-926
https://cea.digitellinc.com/p/s/ccos-conference-to-clinic-highlights-from-the-2024-ash-annual-meeting-lymphomas-927
https://cea.digitellinc.com/p/s/ccos-conference-to-clinic-highlights-from-the-2024-ash-annual-meeting-nonmalignant-hematology-928
https://cea.digitellinc.com/p/s/ccos-conference-to-clinic-highlights-from-the-2024-ash-annual-meeting-leukemias-929
https://cea.digitellinc.com/p/s/ccos-conference-to-clinic-highlights-from-the-2024-ash-annual-meeting-multiple-myeloma-930
https://cea.digitellinc.com/p/s/ccos-conference-to-clinic-highlights-from-the-2024-ash-annual-meeting-myelodysplastic-syndromes-mds-and-myeloproliferative-neoplasms-mpn-931
https://cea.digitellinc.com/p/cf/sts-jan-934
https://cea.digitellinc.com/p/s/when-every-second-counts-the-latest-data-and-expert-guidance-on-antiplatelet-therapy-reversal-for-surgical-professionals-935
https://cea.digitellinc.com/p/cf/applexus-spring-mar-2025-938
https://cea.digitellinc.com/p/s/welcome-plus-advances-in-car-t-cell-therapy-for-patients-with-hematologic-malignancies-939
https://cea.digitellinc.com/p/s/strengthening-the-safety-net-with-advanced-nursing-strategies-for-managing-immunotherapy-related-adverse-events-940
https://cea.digitellinc.com/p/s/session-choice-page-941
https://cea.digitellinc.com/p/s/thrombotic-risk-and-symptom-burden-in-patients-with-polycythemia-vera-identify-when-to-intervene-with-jakafi-r-ruxolitinib-non-cme-educational-session-managed-by-clinical-care-solutions-a-cea-company-942
https://cea.digitellinc.com/p/s/clinic-ready-insights-on-emerging-data-for-current-antibody-drug-conjugates-in-breast-cancer-plus-closing-remarks-943
https://cea.digitellinc.com/p/cf/amda-mar-2025-946
https://cea.digitellinc.com/p/s/addressing-key-challenges-to-rsv-vaccination-in-post-acute-and-long-term-care-947
https://cea.digitellinc.com/p/s/holistic-approaches-to-agitation-associated-with-dementia-due-to-alzheimers-disease-a-long-term-care-perspective-948
https://cea.digitellinc.com/p/cf/uscap-2025-satellites-951
https://cea.digitellinc.com/p/cf/aagp-mar-2025-952
https://cea.digitellinc.com/p/s/transforming-care-in-tardive-dyskinesia-expert-guidance-for-geriatric-psychiatry-practice-955
https://cea.digitellinc.com/p/s/shining-a-light-on-her2-low-and-her2-ultralow-metastatic-breast-cancer-a-pathologists-guide-to-bridging-the-diagnostic-gaps-956
https://cea.digitellinc.com/p/s/refining-approaches-to-overcome-challenges-enhance-consistency-and-standardize-scoring-and-reporting-in-her2-expressing-solid-tumors-958
https://cea.digitellinc.com/p/cf/amcp-apr-2025-961
https://cea.digitellinc.com/p/s/hit-the-ground-running-in-crohns-disease-a-managed-care-guide-to-advanced-biologic-therapies-and-early-interventions-to-improve-long-term-outcomes-962
https://cea.digitellinc.com/p/cf/dermatology-intensive-apr-2025-965
https://cea.digitellinc.com/p/s/leave-the-itch-behind-expert-guidance-for-nps-and-pas-to-leverage-new-therapies-to-help-patients-beat-the-itch-scratch-cycle-966
https://cea.digitellinc.com/p/s/hidradenitis-huddle-comprehensive-diagnosis-and-management-strategies-for-nps-and-pas-to-improve-patient-outcomes-967
https://cea.digitellinc.com/p/s/mastocytosis-mayhem-comprehensive-diagnosis-and-management-strategies-for-nps-and-pas-to-tackle-the-unpredictable-968
https://cea.digitellinc.com/p/cf/psych-update-nppa-may-2025-971
https://cea.digitellinc.com/p/s/opening-remarks-and-critical-screening-and-timely-diagnosis-of-tardive-dyskinesia-in-older-adults-evidence-based-strategies-for-clinical-practice-972
https://cea.digitellinc.com/p/s/advancing-clinical-decision-making-in-mdd-evidence-based-strategies-for-augmentation-switching-and-personalized-treatment-plans-973
https://cea.digitellinc.com/p/s/transforming-patient-centered-schizophrenia-care-exploring-novel-therapeutic-strategies-974
https://cea.digitellinc.com/p/s/session-choice-975
https://cea.digitellinc.com/p/s/leading-with-a-vmat2-inhibitor-for-patients-with-tardive-dyskinesia-976
https://cea.digitellinc.com/p/s/steering-through-anxiety-evidence-based-navigation-for-anxiety-disorders-977
https://cea.digitellinc.com/p/s/puberty-to-menopause-the-impact-of-hormone-fluctuations-on-depression-and-closing-remarks-978
https://cea.digitellinc.com/p/cf/psych-update-md-may-2025-981
https://cea.digitellinc.com/p/s/opening-remarks-and-redefining-schizophrenia-care-exploring-novel-mechanisms-and-clinical-applications-982
https://cea.digitellinc.com/p/s/strategies-for-augmentation-and-switching-in-the-treatment-of-major-depressive-disorder-983
https://cea.digitellinc.com/p/s/reproductive-depression-why-hormones-matter-984
https://cea.digitellinc.com/p/s/when-worry-takes-the-wheel-evidence-based-approaches-for-anxiety-disorders-985
https://cea.digitellinc.com/p/s/the-science-and-soul-of-shaping-the-next-generation-of-psychiatry-professionals-and-closing-remarks-986
https://cea.digitellinc.com/p/cf/cco-satellite-symposia-may-2025-989
https://cea.digitellinc.com/p/s/optimizing-asparaginase-therapy-navigating-evolving-clinical-challenges-in-pediatric-and-aya-all-for-improved-outcomes-990
https://cea.digitellinc.com/p/cf/psychiatry-summit-may-2025-993
https://cea.digitellinc.com/p/s/opening-remarks-and-from-assessment-to-action-case-based-insights-for-bipolar-depression-with-mixed-and-anxious-specifiers-994
https://cea.digitellinc.com/p/s/brain-health-in-focus-dementia-prevention-and-early-diagnosis-in-psychiatric-settings-995
https://cea.digitellinc.com/p/s/beyond-dopamine-innovations-in-schizophrenia-treatment-and-addressing-unmet-needs-996
https://cea.digitellinc.com/p/s/reproductive-depression-why-hormones-matter-997
https://cea.digitellinc.com/p/s/beyond-counting-sheep-evidence-based-approaches-to-insomnia-and-closing-remarks-998